ArticleAmerican journal of nuclear medicine and molecular imaging2026
ACP3-targeted PET imaging agents based on small-molecule ligands for prostate cancer diagnostics and theranostics.
Article in American journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) remains a leading cause of cancer-related morbidity and mortality worldwide, underscoring the need for improved molecular imaging strategies. Although prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has changed prostate cancer imaging and treatment, its clinical utility is limited in some settings by heterogeneous tumor expression and substantial off-target uptake in organs such as the kidneys and salivary glands. Acid phosphatase 3 (ACP3), also known as prostatic acid phosphatase, has regained attention as an alternative prostate-associated target because of its abundant expression in prostate cancer and comparatively low expression in several normal tissues. Recent advances in high-affinity small-molecule ligands, including radiolabeled OncoACP3 derivatives, have enabled the development of ACP3-targeted PET radiopharmaceuticals. Preclinical studies and early clinical investigations demonstrate favorable biodistribution, high tumor-to-background contrast, and the capacity to detect lesions in PSMA-low or PSMA-negative disease. Moreover, ACP3-directed radioligand strategies highlight its potential in theranostic applications. Overall, ACP3 radiopharmaceuticals may provide a complementary approach for precision prostate cancer imaging and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.